No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Stella Chemifa Corporation, a Japanese company established in 1916 and headquartered in Osaka, specializes as a global manufacturer and supplier of inorganic fluorine compounds. Formerly known as Hashimoto Chemical Corporation until its rebranding in 1997, the company offers a comprehensive product portfolio tailored for diverse industrial applications worldwide. For the electronics sector, Stella Chemifa provides essential materials such as hydrofluoric acid, buffered hydrofluoric acid, and various etching solutions used in the production of semiconductors, liquid crystal displays, and solar cells. It also supplies a range of metal fluorides, including calcium, aluminum, and lithium fluoride, crucial for optical applications, alongside lithium hexafluorophosphate for battery manufacturing. Its offerings extend to numerous boron trifluoride compounds, serving as vital reactive catalysts across different chemical processes. Additionally, the company produces anhydrous hydrofluoric acid and 55% hydrofluoric acid, utilized in surface treatment and as more environmentally conscious alternatives to CFCs. Stella Chemifa also supports the nuclear energy industry with potassium fluoroborate and boric acid, and provides tin fluoride (II) USP for products requiring GMP compliance. Beyond these specialized compounds, the company's extensive catalog includes a broad array of other fluorochemicals, such as fluorosilicic acid, various fluorosilicates, fluoroboric acid, diverse fluoroborates, and a selection of ammonium, sodium, and potassium fluorides. Complementing its manufacturing operations, Stella Chemifa offers logistics services for the transportation of specialized chemical substances, high-pressure gases, and hazardous materials. Demonstrating a commitment to innovation, the company is also actively involved in the development of Boron Neutron Capture therapy for cancer treatment.
www.stella-chemifa.co.jpNo one on the platform currently holds 4109.T.
No tracked institution reports a position in 4109.T as of their last filing.
No one on the platform has traded 4109.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.3% | 8.1% | 7.8% | — | — | — |
| Rev. Growth % | 1.4% | 2.3% | ||||
| Profit Margin % | 8.3% | 8.6% | 7.7% | |||
| Free Cash Flow Margin % | 3.9% | 4.9% | 5.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $40.9B | +13.2% | $283.85 | $280.49–$287.21 | — | 1 |
| 2028 | $43.2B | +5.8% | $325.85 | $305.27–$346.43 | — | 2 |
| 2029 | $45.9B | +6.3% | $358.65 | $354.40–$362.90 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.44% |
| $44.2B |
| — |
| 4221.TOkura Industrial Co., Ltd. | $5440.00 | +0.74% | $61.5B | — |
| 4362.TNippon Fine Chemical Co., Ltd. | $2642.00 | +0.19% | $57.3B | — |
Source: Financial Modeling Prep · peers by sector/industry